share_log

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)

HC Wainwright & Co. 维持买入评级,将目标股价调整为$57(进行1-20股票回拨)rigel pharmaceuticals
Benzinga ·  08/09 17:47  · 评级/大行评级

HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy, adjusts target to $57 from $15 (1-20 Reverse Stock Split).

HC Wainwright & Co. 分析师Joseph Pantginis维持Rigel Pharmaceuticals (纳斯达克:rigel pharmaceuticals)的买入评级,将目标价从15美元调整至57美元(1-20股票拆分)。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发